LA JOLLA, Calif.
June 11, 2013
Regulus Therapeutics Inc
. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has named
, Ph.D. as Chairman of its Board of Directors effective immediately.
Dr. Papadopoulos assumes the role of Chairman of the Board from
, Ph.D., who will remain a member of the Board of Directors. Dr. Papadopoulos, who has been a member of the Board since 2008, has more than 30 years of experience in the biotechnology and pharmaceutical industries as an investment banker, board member, company founder and investor. Dr. Papadopoulos is a Board member of several companies including Biogen Idec, Inc. and Exelixis, Inc., where he is Chairman.
"Stelios brings together financial savvy, business ingenuity and scientific creativity," said
, Ph.D., member of the Board and President and CEO of Alnylam Pharmaceuticals, Inc. "I couldn't think of a more accomplished individual to become Chairman of Regulus' Board."
"Stelios' transition to Chairman of the Board comes at a very exciting time for Regulus," said
Kleanthis G. Xanthopoulos
, Ph.D., President and CEO of Regulus. "We've achieved early success under our 'Road to the Clinic' strategy with the recent nomination of our first clinical candidate, RG-101 for the treatment of HCV. Stelios' extensive industry knowledge and experience are perfectly suited to help advance our microRNA candidates into clinical development and position Regulus for continued success and growth."
"Regulus is a benchmark of innovation focused on harnessing the power of a transformative class of novel therapeutics and biomarkers based on microRNAs," said
, Ph.D., Chairman of the Board. "I am excited to help guide our dedicated and talented team as we strive to execute on Regulus' scientific and strategic goals."
Dr. Papadopoulos retired as Vice Chairman of Cowen and Company, LLC in 2006 after six years with the firm where he was an investment banker focused on the biotechnology and pharmaceuticals sectors. Prior to joining Cowen in 2000, Dr. Papadopoulos was an investment banker at PaineWebber Incorporated, most recently serving as Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. Prior to that, he held positions in Equity Research covering the biotechnology industry at Drexel Burnham Lambert and Donaldson, Lufkin & Jenrette. He is a co-founder and Chairman of the Board of Directors of Exelixis, Inc., and a member of the Board of Directors at Biogen Idec, Inc., BG Medicine, Inc. and Joule Unlimited. Additionally, Dr. Papadopoulos was a co-founder and former Board member of Cellzome, Inc. (acquired by GSK in 2012) and Anadys Pharmaceuticals, Inc. (acquired by Roche in 2011).